BPC-157
Also referred to as Body Protection Compound 157, PL 14736.
Status: Investigational. BPC-157 is not an FDA-approved drug product. In 2023 the FDA placed BPC-157 in the category of bulk substances it identified as raising significant safety risks for compounding under section 503A, so availability is restricted and any current status must be verified with a licensed pharmacy and counsel before a prescription is considered.
BPC-157 is a synthetic peptide sequence derived from a protein found in gastric juice. Almost all published work is preclinical, meaning cell and animal studies rather than large human trials. It is not an FDA-approved drug product, and the FDA has identified it as a bulk substance raising significant safety questions for pharmacy compounding. Any discussion of it at GOAL.MD happens inside a physician consultation, not as a product you can order online.
How it is described in the literature
In animal models, researchers describe BPC-157 as interacting with signalling pathways involved in blood vessel formation and with nitric oxide signalling. These descriptions come from laboratory work. How, or whether, those observations translate to people has not been established in adequately sized human trials.
What researchers and clinicians are studying
- Preclinical models of gastrointestinal lining injury
- Animal models of tendon and ligament healing responses
- Signalling pathways related to new blood vessel formation
- Interactions with nitric oxide pathways in laboratory settings
What is not established
- There is no adequately powered human clinical trial demonstrating benefit for injury recovery
- Long-term safety in humans has not been characterised
- Effects on tumour biology are not characterised, which is one reason physicians screen carefully
- Optimal route, exposure, and duration in humans are unknown
Safety and eligibility
- Human safety data are limited, so risk cannot be quantified the way it can for an approved drug
- Product quality varies widely in the unregulated online market, which is a separate risk from the molecule itself
- Because the substance is not approved, there is no standardised adverse-event labelling to consult
How eligibility is evaluated
- A physician reviews your full history, current medications, and goals before discussing whether any peptide is appropriate
- Active or prior cancer history is discussed directly, since growth-related signalling is not characterised in people
- Where evidence does not support use, the physician will say so and suggest options with better support
Generally not appropriate for
- Anyone who is pregnant, planning pregnancy, or breastfeeding
- Anyone with an active malignancy or an undiagnosed mass, absent specialist input
- Anyone seeking a substitute for evaluation of an untreated injury or an undiagnosed symptom
Frequently asked questions
Is BPC-157 FDA-approved?
No. BPC-157 is not an FDA-approved drug product for any indication. The FDA has also identified it as a bulk substance that raises significant safety questions for use in pharmacy compounding under section 503A.
Can I order BPC-157 from GOAL.MD?
No. This page is educational. GOAL.MD does not sell BPC-157, and nothing here is an offer to dispense it. Prescribing decisions are made only by a licensed physician after an individual evaluation.
Why do so many articles describe strong results?
Most of those descriptions come from animal and cell studies. Preclinical results frequently do not reproduce in humans, and describing them as if they were human outcomes overstates what is known.
What does 'research peptide' mean on the products sold online?
It generally means the seller is not offering it as a medicine for human use. Those products are outside pharmacy oversight, and their identity, purity, and sterility are unverified.
This page is educational. Nothing here can be ordered from this page and nothing here is a prescription or medical advice. Compounded preparations are not FDA-approved. Talk with a GOAL.MD physician at goal.md/intake or call or text 314-907-3103.
Medically reviewed by Dr. Michael Mimlitz, MD (NPI 1508891870), Chief Physician of GOAL.MD. Last reviewed 2026-08-12.